Background. Eravacycline is a novel, fully synthetic fluorocycline antibiotic that was evaluated in three comparator-controlled studies for the treatment of complicated intra-abdominal infections (cIAI). The objective of this analysis was to evaluate the safety profile of eravacycline 1 mg/kg IV q12h for the treatment of cIAI.
Methods. Pooled data from one phase 2 and two phase 3 (IGNITE1 and IGNITE4) clinical trials in cIAI were analyzed. Patients in the trials were randomized to receive eravacycline 1 mg/kg IV q12h, ertapenem 1 g IV q24h, or meropenem 1 g IV q8h for 4-14 days. Overall treatment-emergent adverse events (TEAEs), serious TEAEs, and laboratory assessments were evaluated.
Results. Five hundred seventy-six patients were treated with eravacycline 1 mg/kg IV q12h and 547 patients with comparators (ertapenem and meropenem). Demographic and baseline characteristics were similar among the groups. Overall summary and common TEAEs are presented in Table 1 . None of the serious TEAEs or those leading to death were related to the study drug. Clinically notable laboratory abnormalities were relatively uncommon and occurred at similar frequencies in eravacycline-and comparator-treated patients. Comparators include ertapenem 1 g IV q24h and meropenem 1 g IV q8h.
